The Company’s Board of Directors resolved to revise 2023 Employee Stock Option Issuance and Subscription Rules

Announcement of the Consolidated Financial Statements for the second quarter of 2023 were approved by the Board of Directors

OBI licensed “Nectin-4 Human Antibody” rights from Ablexis, LLC

The Company’s Board of Directors resolved to revise 2023 Employee Stock Option Issuance and Subscription Rules

The Company’s Board of Directors nominated Yun Yen to serve as the Chairman of the Board

Announcement that the institutional director of OBI, Sheng Cheng Investment Co., Ltd., changes its representative

Announcement of 2023 shareholders' meeting’s resolution to lift the non-competition restrictions for directors

Announcement of the Company’s important resolutions of the 2023 annual shareholders’ meeting

Announcement of By-election of the director at the 2023 Annual Shareholders’ Meeting

Announcement on behalf of Amaran of important resolutions of the 2023 annual shareholders’ meeting